A5052175895- Ovarian cancer diagnosis and treatment
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Virus-based gene therapy research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Endometrial and Cervical Cancer Treatments
- Cancer Research and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Intraperitoneal and Appendiceal Malignancies
- Immune Response and Inflammation
- Pain Management and Opioid Use
- BRCA gene mutations in cancer
- Endometriosis Research and Treatment
- Cancer, Lipids, and Metabolism
- Anesthesia and Pain Management
- PARP inhibition in cancer therapy
- Reproductive System and Pregnancy
- Cell Adhesion Molecules Research
- Cancer Risks and Factors
- Renal cell carcinoma treatment
- Peptidase Inhibition and Analysis
- Bladder and Urothelial Cancer Treatments
Roswell Park Comprehensive Cancer Center
2016-2025
University of Pennsylvania Health System
2023
Hospital of the University of Pennsylvania
2023
Gynecologic Oncology Group
2022
University of Debrecen
2004-2022
Abramson Cancer Center
2021
Cancer Research Center
2015-2021
University of Pennsylvania
2012-2021
Northwestern University
2012-2019
Yale Cancer Center
2017
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States and country’s fifth most common mortality women. A major challenge treating that patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating ovary, fallopian tube, or peritoneum, as these are all managed a similar manner. Most recommendations based on data with subtypes─high-grade serous grade 2/3 endometrioid. The also include specifically for less cancers,...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years diagnosis. A major challenge treating that most have advanced disease at initial The best outcomes are observed whose primary treatment includes complete resection all visible plus combination platinum-based chemotherapy. Research efforts focused on neoadjuvant treatments may improve resectability, as well systemic therapies providing improved long-term...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations diagnosis, evaluation, treatment, and follow-up ovarian, fallopian tube, primary peritoneal cancers. These Insights summarize panel discussion behind recent important updates to guidelines, including revised guidance on alternative chemotherapy regimens advanced age and/or...
Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality life, representing an unmet need tolerable effective therapies.To assess the efficacy safety a combination pembrolizumab with bevacizumab oral metronomic cyclophosphamide in patients platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, primary peritoneal cancer.This open-label, single-arm phase 2 cohort study enrolled from September 6, 2016,...
<h3>Importance</h3> Opioids are routinely prescribed for postoperative home pain management most patients in the United States, with limited evidence of amount needed to be dispensed. Opioid-based treatment often adversely affects recovery. Prescribed opioids increase risk chronic opioid use, abuse, and diversion contribute current epidemic. <h3>Objective</h3> To evaluate whether after hospital discharge, postsurgical acute can effectively managed a markedly reduced number doses. <h3>Design,...
2538 Background: There is a high unmet medical need for effective treatments patients with recurrent, metastatic, or persistent cervical cancer. Most are young and survival rates poor. ORR second line therapies between 4 14% chemotherapy recently approved immunotherapy. Adoptive cell transfer using tumor infiltrating lymphocytes (TIL) have demonstrated durable responses in some recurrent cancer thus offering the potential long-term disease control. Methods: Study C-145-04 an ongoing,...
Epithelial ovarian cancer (EOC) often presents with metastases and ascites. Granulocytic myeloid-derived suppressor cells are an immature population that impairs antitumor immunity. Since suppressive granulocytes in the ascites of patients newly diagnosed EOC were morphologically mature, we hypothesized PMN rendered tumor microenvironment (TME). Circulating from not but acquired a phenotype (defined as ≥1 log10 reduction anti-CD3/CD28-stimulated T cell proliferation) after supernatant...
Regulatory CD4
To uncover underlying mechanisms associated with failure of indoleamine 2,3-dioxygenase 1 (IDO1) blockade in clinical trials, we conducted a pilot, window-of-opportunity study 17 patients newly diagnosed advanced high-grade serous ovarian cancer before their standard tumor debulking surgery. Patients were treated the IDO1 inhibitor epacadostat, and immunologic, transcriptomic, metabolomic characterization microenvironment was undertaken baseline posttreatment biopsies. inhibition resulted...
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations this disease. These Insights detail how the evolution of use PARP inhibitors as maintenance single-agent regimens ovarian cancer informed panel in guidelines.
Abstract T-cell activation and expansion in the tumor microenvironment (TME) are critical for antitumor immunity. Neutrophils TME acquire a complement-dependent suppressor phenotype that is characterized by inhibition of proliferation through mechanisms distinct from those myeloid-derived cells. In this study, we used ascites fluid supernatants (ASC) patients with ovarian cancer as an authentic component to evaluate effects ASC on neutrophil function neutrophil-driven immune suppression....
Background: Across Europe, tobacco use is more prevalent among secondary school students attending vocational tracks compared with academic tracks. The purpose of the present study to describe trends in social inequality daily smoking adolescents between 2002 and 2010 by addressing both absolute (prevalence difference tracks) relative ratio) seven European countries. Methods: Analyses were based on data from 15-year-olds who participated Health Behaviour School-aged Children 2002, 2006...
Abstract Purpose: Chemokines are implicated in T-cell trafficking. We mapped the chemokine landscape advanced stage ovarian cancer and characterized expression of cognate receptors autologous dendritic cell (DC)–vaccine primed T cells context cell-based immunotherapy. Experimental Design: The all known human chemokines patients with primary was analyzed on two independent microarray datasets validated tissue microarray. Peripheral blood from five HLA-A2 recurrent cancer, who previously...
Highlights•Mouse mutations Pum1/Pum2 cause a gene dosage-dependent global reduction in body size•PUM promotes G1-S transition by repressing translation of Cdkn1b via binding its 3′ UTR•Cdkn1b mutation partially rescues reduced cell proliferation and size Pum1 mice•Auto- reciprocally regulated PUM expression contributes to precise control sizeSummaryBody organ regulation mammals involves multiple signaling pathways remains largely enigmatic. Here, we report that Pum2, which encode highly...
T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific prolonged OC survival. Here, we hypothesize adding acetylsalicylic acid (ASA) low-dose interleukin (IL)-2 would increase the efficacy in recurrent advanced phase I trial (NCT01132014). By ASA IL-2 to OCDC-Bev-Cy regimen, vaccine-specific...
Modulation of the expression and activity plasma membrane ion channels is one mechanisms by which immune cells can regulate their intracellular Ca(2+) signaling pathways required for proliferation and/or differentiation. Voltage-gated K+ channels, inwardly rectifying Ca(2+)-activated have been described to play a major role in controlling potential lymphocytes professional APCs, such as monocytes, macrophages, dendritic (DCs). Our study aimed at characterization identification expressed...
Bevacizumab has demonstrated significant benefit in recurrent ovarian, fallopian tube and peritoneal cancer (OC), but its optimal position within the sequence of systemic therapies remains controversial. Since rebound progression after bevacizumab been observed other cancers, because is incorporated several regimens used setting, duration treatment may impact survival. We sought to identify whether earlier exposure associated with prolonged therapy survival by conducting a multi-institution...
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) been approved by the US Food and Drug Administration for of cervical cancer endometrial cancer, offering durable responses some patients. In addition, many immunotherapy strategies are under investigation earlier stages disease or in other cancers, such as ovarian rare tumors. While integration ICIs into standard care has improved outcomes patients, their use...
Background Perturbation of the mechanistic target rapamycin (mTOR) pathway can instruct effector versus memory cell fate tumor antigen-specific T cells in preclinical models. In this study, we sought to understand impact (sirolimus), an mTOR inhibitor, on reprogramming vaccine-induced enhance responses patients with solid tumors following completion their standard therapy. Methods We conducted three phase I clinical trials employing New York esophageal squamous carcinoma-1 (NY-ESO-1)...
To determine the efficacy, progression-free survival (PFS) and overall (OS) for combination of intravenous bevacizumab oral cyclophosphamide in heavily pretreated patients with recurrent ovarian carcinoma.A retrospective review was performed all carcinoma treated 10 mg/kg every 14 days 50 mg daily between January 2006 December 2010. Response to treatment determined by Evaluation Criteria Solid Tumors criteria and/or CA-125 levels.Sixty-six eligible were identified. Median age 53 years....